Código QR (código de barras bidimensional)

Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study

Shihan Zhou,1,* Ru Yao,2,* Mengqi Zhang,1 Mingxia Jiang,1 Jiaxuan Liu,1 Mingxiao Li,1 Fei Ma,1 Bo Pan,2 Qiao Li1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union...

ver descrição completa

Na minha lista:
Principais autores: Zhou S, Yao R, Zhang M, Jiang M, Liu J, Li M, Ma F, Pan B, Li Q
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2026-05-01
coleção:Breast Cancer: Targets and Therapy
Assuntos:
Dalpiciclib
CDK4/6 inhibitor
HR+/HER2- breast cancer
endocrine resistance
cross-line therapy
Acesso em linha:https://www.dovepress.com/efficacy-safety-and-prognostic-factors-of-dalpiciclib-combined-with-en-peer-reviewed-fulltext-article-BCTT
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados